Unintentional monotherapy in rheumatoid arthritis patients receiving tofacitinib and drug survival rate of tofacitinib

İnanç, N.Abacar, K.Öztürk, M. A.Tufan, A.Karadeniz, H.Sarı, I.Can, G.Erez, Y.Pehlivan, YavuzDalkılıç, EdizOcak, TuğbaCefle, A.Yazıcı, A.Şenel, A.Akar, S.Ediboğlu, E. DurakKoca, S. S.Sağır, R. PişkinYılmaz, S.Gülcemal, S.Gündüz, O. SoysalBaşıbüyük, C. S.Alkan, S.Cesur, T. Y.Önen, F.2024-11-282024-11-282022-06-010003-4967https://doi.org/10.1136/annrheumdis-2022-eular.5102https://ard.bmj.com/content/81/Suppl_1/1338.1https://hdl.handle.net/11452/48638Bu çalışma, 01-04, Haziran 2022 tarihlerinde Location Copenhagen[Danimarka]’da düzenlenen Annual European Congress of Rheumatology (EULAR) Kongresi‘nde bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/openAccessScience & technologyLife sciences & biomedicineRheumatologyUnintentional monotherapy in rheumatoid arthritis patients receiving tofacitinib and drug survival rate of tofacitinibMeeting Abstract000850279005278133813388110.1136/annrheumdis-2022-eular.51021468-2060